New research explains repeated infection by some viruses

Apr 01, 2010

New research conducted at the Oregon Health & Science University Vaccine and Gene Therapy Institute explains how a virus that has already infected up to 80 percent of the American population can repeatedly re-infect individuals despite the presence of a strong and long-lasting immune response. The research involves cytomegalovirus (CMV), which infects 50 percent to 80 percent of the U.S. population before age 40. Details of the new findings are printed in this week's online edition of the journal Science.

For most people, CMV infection goes undetected and they do not become seriously ill. However, in vulnerable populations with weaker immune systems, such as developing and newborn infants, organ donor recipients and human immunodeficiency (HIV) patients, CMV poses a very serious and potentially deadly risk. Some 8,000 children suffer disabilities caused by CMV each year.

"CMV is one of a few virus types that can efficiently re-infect individuals who are already persistently infected by this virus," explained Louis Picker, M.D., associate director of the OHSU VGTI and director of the VGTI's vaccine program. He also serves as director of the Division of Pathobiology and Immunology at the Oregon National Primate Research Center at OHSU.

"When most viruses infect a host, the remembers the disease and protects against re-infection. This is the case with smallpox, seasonal strains of flu and several other viruses. This immune system reaction is also the reason why vaccines made with weakened or dead viruses work against these pathogens. In the case of CMV, the body's immune system is continuously stimulated by ongoing, low-level persistent infection, but yet CMV is still able to re-infect. This research explains how CMV is able to overcome this immune response so that re-infection occurs."

By studying monkeys at the Oregon National Primate Research Center naturally infected with CMV, researchers demonstrated that CMV re-infection can only take place when the virus is able to evade a key portion of the immune system called CD8+ T . These white blood cells, also called "killer T cells," attack and kill infected cells as a part of the body's system. Killer T cells identify infected cells through the presence of molecules on the outside of cells called MHC-I. MHC-I molecules present little snippets of viral proteins to the T cells, thus signaling when a cell is infected. T cells save infected tissues by eliminating infected cells.

"CMV evades these alert systems by making genes that disrupt the MHC-I molecules' ability to communicate an ongoing infection to the T cells. In essence, CMV is able to cutoff an infected cell's call for elimination. This allows CMV to overcome this critical immune barrier during re-infection," explained Klaus Frueh, Ph.D., a senior scientist at the VGTI and a professor of molecular microbiology and immunology in the OHSU School of Medicine.

The results of this study primarily illustrate the significant barriers to creating a vaccine that will prevent CMV infection. However, on a positive note, this research also explains why CMV might be a useful viral vaccine vector. Vaccine vectors are modified viruses that carry genetic material from other pathogens into the body, thus vaccinating against these pathogens. However, because the body also makes an immune response against the vector, current vaccine vectors can only be used once. Because of their ability to overcome vector-directed immunity, CMV viral vectors may be used repeatedly to stimulate an against a variety of pathogens, including other viruses such as HIV and hepatitis C, but also malaria parasites and tuberculosis bacteria. This research may therefore help aid in the development of such vaccines.

This research was primarily funded by the National Institutes of Health, the International AIDS Vaccine Initiative.

Explore further: Study of gene mutations in aplastic anemia may help optimize treament

Related Stories

New vaccine prevents CMV infection and disease in mice

Jun 22, 2007

Researchers at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences have patented a strategy for developing a human vaccine to prevent against Human Cytomegalovirus (hCMV) infection ...

Vaccine against CMV shows promise in clinical trial

Mar 18, 2009

A new vaccine has the potential to be the first to prevent maternal and congenital cytomegalovirus (CMV) infection, according to a University of Alabama at Birmingham (UAB) study published in the March 19 edition of the New En ...

The bowels of infection

Oct 21, 2009

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," ...

Common virus could cause high blood pressure

May 15, 2009

( -- A new study suggests for the first time that cytomegalovirus (CMV), a common viral infection affecting between 60 and 99 percent of adults worldwide, is a cause of high blood pressure, a leading ...

Recommended for you

A high-fat diet may alleviate mitochondrial disease

Jun 30, 2015

Mice that have a genetic version of mitochondrial disease can easily be mistaken for much older animals by the time they are nine months old: they have thinning grey hair, osteoporosis, poor hearing, infertility, ...

Cheek muscles hold up better than leg muscles in space

Jun 30, 2015

It is well known that muscles need resistance (gravity) to maintain optimal health, and when they do not have this resistance, they deteriorate. A new report published in the July 2015 issue of The FASEB Journal, however, sugges ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.